In the Claims

Claim 1 (Currently amended).

An amended recombinant cell (ARC) comprising at least one heterologous gene, said at least one heterologous gene encoding a chemokine or a cytokine, wherein said amended recombinant cell is *Pseudomonas fluorescens*.

Claim 2 (Previously Presented).

The ARC according to claim 1, wherein said ARC further comprises at least one additional heterologous gene that encodes IL-1, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-11, IL-15, Il-16, Il-18, IL-23, IL-24, erythropoietin, G-CSF, M-CSF, platelet derived growth factor (PDGF), MSF, FLT-3 ligand, EGF, fibroblast growth factor (FGF); aFGF (FGF-1); bFGF (FGF-2); FGF-3; FGF-4; FGF-5; FGF-6; FGF-7; insulin-like growth factor 1 (IGF-1); IGF-2; vascular endothelial growth factor (VEGF); IFN-γ; IFN-α; IFN-β; leukemia inhibitory factor (LIF); ciliary neurotrophic factor (CNTF); oncostatin M; stem cell factor (SCF); TGF-α; TGF-β1; TGF-β2; a chemokine selected from the group consisting of BCA-1/BLC-1, BRAK/Kec, CXCL16, CXCR3, ENA-78/LIX, Eotaxin-1, Eotaxin-2/MPIF-2, Exodus-2/SLC, Fractalkine/Neurotactin, GROalpha/MGSA, HCC-1, I-TAC, Lymphotactin/ATAC/SCM, MCP-1/MCAF, MCP-3, MCP-4, MDC/STCP-1, ABCD-1, MIP-1α, MIP-1β, MIP-2α/GROβ, MIP-3α/Exodus/LARC, MIP-3β/Exodus-3/ELC, MIP-4/PARC/DC-CK1, PF-4, RANTES, SDF1α, TARC, and TECK; or a cytokine or chemokine as provided in Tables 1, 8, and 9.

Claim 3 (Previously Presented).

The ARC according to claim 1, wherein said at least one heterologous gene encodes IFN-γ.

Claim 4 (Original).

The ARC according to claim 3, wherein said IFN-γ is bovine, avian, fish, or human.

Claim 5 (Original).

The ARC according to claim 4, wherein said IFN-γ is bovine.

Claim 6 (Original).

The ARC according to claim 4, wherein said avian IFN-γ is chicken IFN-γ.

Claim 7 (Previously Presented).

The ARC according to claim 2, wherein said at least one additional heterologous gene encodes IFN-α.

Claims 8-9 (Canceled).

Claim 10 (Currently Amended).

A composition comprising an~~The~~ ARC according to claim 1 and ~~, further comprising~~ a carrier.

Claim 11 (Withdrawn-currently amended).

A method of inducing or accelerating an immune response in an individual to an antigen or immunogen comprising the step of administering, to an individual:

amended recombinant *Pseudomonas fluorescens* cells (ARCs) comprising at least one heterologous gene encoding a chemokine or a cytokine; or

a composition comprising amended recombinant *Pseudomonas fluorescens* cells (ARCs) comprising at least one heterologous gene encoding a chemokine or a cytokine.

Claim 12 (Withdrawn).

The method according to claim 11, wherein said method further comprises the administration of an antigen of interest.

Claim 13 (Withdrawn).

The method according to claim 12, further comprising the administration of lipopolysaccharide (LPS).

Claim 14 (Withdrawn).

The method according to claim 11, wherein said heterologous gene encodes IFN-γ.

Claim 15 (Withdrawn).

The method according to claim 14, wherein said IFN-γ is bovine, avian, fish, or human.

Claim 16 (Withdrawn).

The method according to claim 15, wherein said IFN-γ is bovine.

Claim 17 (Withdrawn).

The method according to claim 15, wherein said avian IFN-γ is chicken IFN-γ.

Claim 18 (Withdrawn).

The method according to claim 11, wherein the ARCs co-express at least one antigen of interest.

Claims 19-40 (Canceled).

Claim 41 (Previously Presented).

The ARC according to claim 3, wherein said ARC further comprises at least one additional heterologous gene that encodes IFN-α.

Claims 42-47 (Canceled).

Claim 48 (New-Withdrawn).

The method according to claim 11, wherein said ARCs further comprise at least one additional heterologous gene that encodes IL-1, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-11, IL-15, Il-16, Il-18, IL-23, IL-24, erythropoietin, G-CSF, M-CSF, platelet derived growth factor (PDGF), MSF, FLT-3 ligand, EGF, fibroblast growth factor (FGF); aFGF (FGF-1); bFGF (FGF-2); FGF-3; FGF-4; FGF-5; FGF-6; FGF-7; insulin-like growth factor 1 (IGF-1); IGF-2; vascular endothelial growth factor (VEGF); IFN-γ; IFN-α; IFN-β; leukemia inhibitory factor (LIF); ciliary neurotrophic factor (CNTF); oncostatin M; stem cell factor (SCF); TGF-α; TGF-β1; TGF-β2; a chemokine selected from the group consisting of BCA-1/BLC-1, BRAK/Kec, CXCL16, CXCR3, ENA-78/LIX, Eotaxin-1, Eotaxin-2/MPIF-2, Exodus-2/SLC, Fractalkine/Neurotactin, GROalpha/MGSA, HCC-1, I-TAC, Lymphotactin/ATAC/SCM, MCP-1/MCAF, MCP-3, MCP-4, MDC/STCP-1, ABCD-1, MIP-1α, MIP-1β, MIP-2α/GROβ, MIP-3α/Exodus/LARC, MIP-3β/Exodus-3/ELC, MIP-4/PARC/DC-CK1, PF-4, RANTES, SDF1α, TARC, and TECK; or a cytokine or chemokine as provided in Tables 1, 8, and 9.

Claim 49 (New-Withdrawn).

The method according to claim 48, wherein said at least one additional heterologous gene encodes IFN-α.

Claim 50 (New-Withdrawn).

The method according to claim 14, wherein said ARCs further comprise at least one additional heterologous gene that encodes IFN-α.